320 related articles for article (PubMed ID: 16926139)
1. Clinical evaluation of recombinant factor VIII preparation (Kogenate) in previously treated patients with hemophilia A: descriptive meta-analysis of post-marketing study data.
Yoshioka A; Fukutake K; Takamatsu J; Shirahata A;
Int J Hematol; 2006 Aug; 84(2):158-65. PubMed ID: 16926139
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A.
Yoshioka A; Fukutake K; Takamatsu J; Shirahata A;
Int J Hematol; 2003 Dec; 78(5):467-74. PubMed ID: 14704043
[TBL] [Abstract][Full Text] [Related]
3. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation.
Lusher J; Abildgaard C; Arkin S; Mannucci PM; Zimmermann R; Schwartz L; Hurst D
J Thromb Haemost; 2004 Apr; 2(4):574-83. PubMed ID: 15102011
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting.
Musso R; Santagostino E; Faradji A; Iorio A; van der Meer J; Ingerslev J; Lambert T; Maas-Enriquez M; Gorina E;
Thromb Haemost; 2008 Jan; 99(1):52-8. PubMed ID: 18217134
[TBL] [Abstract][Full Text] [Related]
5. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review.
Hassan S; Cannavò A; Gouw SC; Rosendaal FR; van der Bom JG
J Thromb Haemost; 2018 Jun; 16(6):1055-1068. PubMed ID: 29665204
[TBL] [Abstract][Full Text] [Related]
6. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group.
Abshire TC; Brackmann HH; Scharrer I; Hoots K; Gazengel C; Powell JS; Gorina E; Kellermann E; Vosburgh E
Thromb Haemost; 2000 Jun; 83(6):811-6. PubMed ID: 10896230
[TBL] [Abstract][Full Text] [Related]
7. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).
Bacon CL; Singleton E; Brady B; White B; Nolan B; Gilmore RM; Ryan C; Keohane C; Jenkins PV; O'Donnell JS
Haemophilia; 2011 May; 17(3):407-11. PubMed ID: 21382134
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, prophylactic effects, and safety of a new recombinant FVIII formulated with sucrose (BAY 14-2222) in Japanese patients with hemophilia A.
Shirahata A; Fukutake K; Takamatsu J; Shima M; Yoshioka A
Int J Hematol; 2000 Jul; 72(1):101-7. PubMed ID: 10979218
[TBL] [Abstract][Full Text] [Related]
9. Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies.
Mannucci PM; Franchini M
Blood Transfus; 2017 Jul; 15(4):365-368. PubMed ID: 27483484
[TBL] [Abstract][Full Text] [Related]
10. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
Rubinger M; Lillicrap D; Rivard GE; Teitel J; Carcao M; Hensman C; Walker I;
Haemophilia; 2008 Mar; 14(2):281-6. PubMed ID: 18194308
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII.
Gringeri A; Tagliaferri A; Tagariello G; Morfini M; Santagostino E; Mannucci P;
Br J Haematol; 2004 Aug; 126(3):398-404. PubMed ID: 15257713
[TBL] [Abstract][Full Text] [Related]
12. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. German Kogenate Study Group.
Aygören-Pürsün E; Scharrer I
Thromb Haemost; 1997 Nov; 78(5):1352-6. PubMed ID: 9408018
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: a long-term, multicentre clinical study in Japan.
Yoshioka A; Shima M; Fukutake K; Takamatsu J; Shirahata A;
Haemophilia; 2001 May; 7(3):242-9. PubMed ID: 11380627
[TBL] [Abstract][Full Text] [Related]
14. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation.
Kreuz W; Gill JC; Rothschild C; Manco-Johnson MJ; Lusher JM; Kellermann E; Gorina E; Larson PJ;
Thromb Haemost; 2005 Mar; 93(3):457-67. PubMed ID: 15735795
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors in Severe Hemophilia A: 25-Year Experience in Slovakia.
Batorova A; Jankovicova D; Morongova A; Bubanska E; Prigancova T; Horakova J; Machyniakova M; Cervenka J; Chandoga J; Böhmer D; Mistrik M
Semin Thromb Hemost; 2016 Jul; 42(5):550-62. PubMed ID: 27235830
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa).
Franchini M; Mannucci PM
Expert Opin Drug Saf; 2017 Mar; 16(3):405-410. PubMed ID: 28103444
[TBL] [Abstract][Full Text] [Related]
17. Measurement of anti-factor VIII IgG, IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII. Kogenate Japanese Clinical Study Group.
Shima M; Sawamoto Y; Nakai H; Kamisue S; Murakami T; Morichika S; Tanaka I; Hayashi K; Yoshioka A
Int J Hematol; 1995 Jul; 62(1):35-43. PubMed ID: 7670006
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study.
Kim SK; Yoo KY; Lee KS; Hwang T; Choi YM; Choi EJ; Park SK
J Korean Med Sci; 2018 Jan; 33(1):e5. PubMed ID: 29215814
[TBL] [Abstract][Full Text] [Related]
19. First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development.
Lusher JM
Semin Thromb Hemost; 2002 Jun; 28(3):273-6. PubMed ID: 12098088
[TBL] [Abstract][Full Text] [Related]
20. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group.
Bray GL; Gomperts ED; Courter S; Gruppo R; Gordon EM; Manco-Johnson M; Shapiro A; Scheibel E; White G; Lee M
Blood; 1994 May; 83(9):2428-35. PubMed ID: 8167332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
